Clinical trial
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating…
NCT00095225 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00095225 |
|---|---|
| Title | A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer) |
| Official title | A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy (Docetaxel or Pemetrexed) or Tarceva (Erlotinib) Compared With Chemotherapy (Docetaxel or Pemetrexed) Alone for Treatment of Recurrent or Refractory Non-Small Cell… |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma, Neoplasm Recurrence, Local |
| Intervention type | Drug |
| Interventions | Avastin (bevacizumab), Tarceva (erlotinib HCl) |
| Enrollment | 122 |
| Start date | Jul 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Nov 2, 2004 |
| Last update posted | Jan 29, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: